New study checks liver impact on lung cancer drug
NCT ID NCT07538973
First seen Apr 28, 2026 · Last updated Jun 09, 2026 · Updated 5 times
Summary
This early-phase study looks at how a new lung cancer drug (anecatibin fumarate) moves through the body in people with different levels of liver function. It will compare 24 adults with impaired liver function to those with normal liver function. The goal is to understand safety and drug levels, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qingdao University Affiliated Hospital
Qingdao, Shandong, 266000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xiamen Traditional Chinese Medicine Hospital
Xiamen, Fujian, 361000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhengzhou Sixth People's Hospital
Zhengzhou, Henan, 450015, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.